Other Events ·
Keros Therapeutics, Inc. filed a Form 8-K to furnish its August 2026 corporate presentation under Regulation FD
KROSKeros Therapeutics, Inc.
Keros Therapeutics, Inc. filed a Form 8-K to furnish its August 2026 corporate presentation under Regulation FD. The filing updates investor materials regarding the company's pipeline of TGF-β superfamily modulators, specifically rinvatercept (KER-065) and elritercept (KER-050). Rinvatercept is in Phase 2 trials for Duchenne muscular dystrophy with initial data expected in early 2027, while elritercept is under a global license agreement with Takeda Pharmaceuticals following a $200 million upfront payment. Keros Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for neuromuscular and hematologic disorders.